Primary Results From Impassion131, a Double-Blind Placebo-Controlled Randomized Phase 3 Trial of First-Line Paclitaxel +/- Atezolizumab for Unresectable Locally Advanced/Metastatic Triple-Negative Breast Cancer

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2020年 / 18卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：11 / 12
页数：2
相关论文
共 50 条
  • [41] A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze)
    Loibl, Sibylle
    Jackisch, Christian
    Seiler, Sabine
    Rastogi, Priya
    Huober, Lens
    Denkert, Carsten
    Schneeweiss, Andreas
    Hanusch, Claus
    Fasching, Peter A.
    Blohmer, Jens-Uwe
    Untch, Michael
    Rhiem, Kerstin
    Solbach, Christine
    Nekljudova, Valentina
    Costantino, Joseph
    Wolmark, Norman
    Geyer, Charles
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 24 - 25
  • [42] Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation
    Miles, David
    Cameron, David
    Bondarenko, Igor
    Manzyuk, Lyudmila
    Alcedo, Juan Carlos
    Lopez, Roberto Ivan
    Im, Seock-Ah
    Canon, Jean-Luc
    Shparyk, Yaroslav
    Yardley, Denise A.
    Masuda, Norikazu
    Ro, Jungsil
    Denduluri, Neelima
    Hubeaux, Stanislas
    Quah, Cheng
    Bais, Carlos
    O'Shaughnessy, Joyce
    EUROPEAN JOURNAL OF CANCER, 2017, 70 : 146 - 155
  • [43] Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study
    Mavratzas, A.
    Baek, S.
    Gerber, B.
    Schmidt, M.
    Moebus, V
    Foerster, F.
    Grischke, E. M.
    Fasching, P.
    Strumberg, D.
    Solomayer, E.
    Klare, P.
    Windemuth-Kieselbach, C.
    Hartmann, S.
    Schneeweiss, A.
    Marine, F.
    BREAST, 2019, 45 : 22 - 28
  • [44] First-line serplulimab in metastatic colorectal cancer: Phase 2 results of a randomized, double-blind, phase 2/3 trial
    Wang, Zi-Xian
    Peng, Junjie
    Liang, Xinjun
    Cheng, Ying
    Deng, Yanhong
    Chen, Kehe
    Zhang, Mingjun
    Zhang, Jingdong
    Wang, Wei
    Cao, Bangwei
    Jin, Yongdong
    Sun, Meili
    Lin, Yuan
    Luo, Suxia
    Li, Zhen
    Yang, Liu
    Ke, Ying
    Yu, Haoyu
    Li, Jing
    Wang, Qingyu
    Zhu, Jun
    Wang, Feng
    Xu, Rui-Hua
    MED, 2024, 5 (09):
  • [45] Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial
    Saghatelyan, Tatul
    Tananyan, Armen
    Janoyan, Naira
    Tadevosyan, Anna
    Petrosyan, Hasmik
    Hovhannisyan, Araxia
    Hayrapetyan, Lidia
    Arustamyan, Mikael
    Arnhold, Juergen
    Rotmann, Andre-Robert
    Hovhannisyan, Areg
    Panossian, Alexander
    PHYTOMEDICINE, 2020, 70
  • [46] Tumour mutational burden and clinical outcomes with first-line atezolizumab and nab-paclitaxel in triple-negative breast cancer: Exploratory analysis of the phase III IMpassion130 trial
    Emens, L. A.
    Molinero, L.
    Adams, S.
    Rugo, H. S.
    Schneeweiss, A.
    Dieras, V.
    Iwata, H.
    Barrios, C. H.
    Nechaeva, M.
    Winer, E. P.
    Chang, C. W.
    Chui, S. Y.
    Schmid, P.
    Loi, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S360 - S361
  • [47] DURVALUMAB, IN COMBINATION WITH AND FOLLOWING CHEMORADIOTHERAPY, IN LOCALLY ADVANCED CERVICAL CANCER: RESULTS FROM THE PHASE 3 INTERNATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED CALLA TRIAL
    Monk, Bradley
    Toita, Takafumi
    Wu, Xiaohua
    Carlos Limon, Juan
    Zhou, Qi
    Tarnawski, Rafal
    Mandai, Masaki
    Shapira-Frommer, Ronnie
    Mahantshetty, Umesh
    Estevez-Diz, Maria Del Pilar
    Ramirez Godinez, Francisco
    Varga, Szilvia
    Leiva Galvez, Manuel Humberto
    Lee, Jung-Yun
    Kreynina, Yulia
    Howells, Kathryn
    Wildsmith, Sophie
    Dry, Hannah
    Nunes, Ana
    Mayadev, Jyoti
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A2 - A3
  • [48] Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI)
    Yardley, Denise Aysel
    Bosserman, Linda D.
    Peacock, Nancy Walker
    Favret, Anne
    Morgan, Susan Kay
    Priego, Victor M.
    Bass, J. David
    Griner, Paula L.
    Burris, Howard A.
    Hainsworth, John D.
    O'Shaughnessy, Joyce
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial
    Colombo, Nicoletta
    Biagioli, Elena
    Harano, Kenichi
    Galli, Francesca
    Hudson, Emma
    Antill, Yoland
    Choi, Chel Hun
    Rabaglio, Manuela
    Marme, Frederic
    Marth, Christian
    Parma, Gabriella
    Farinas-Madrid, Lorena
    Nishio, Shin
    Allan, Karen
    Lee, Yeh Chen
    Piovano, Elisa
    Pardo, Beatriz
    Nakagawa, Satoshi
    Mcqueen, John
    Zamagni, Claudio
    Manso, Luis
    Takehara, Kazuhiro
    Tasca, Giulia
    Ferrero, Annamaria
    Tognon, Germana
    Lissoni, Andrea Alberto
    Petrella, Mariacristina
    Laudani, Maria Elena
    Rulli, Eliana
    Uggeri, Sara
    Ginesta, M. Pilar Barretina
    LANCET ONCOLOGY, 2024, 25 (09): : 1135 - 1146
  • [50] A randomized, double-blind, phase III trial of neoadjuvant chemotherapy (NACT) with atezolizumab/placebo in patients (pts) with triple-negative breast cancer (TNBC) followed by adjuvant continuation of atezolizumab/placebo (GeparDouze)
    Loibl, S.
    Rastogi, P.
    Seiler, S.
    Jackisch, C.
    Lucas, P. C.
    Denkert, C.
    Poklepovic, A.
    Moreno, F.
    Mamounas, E. P.
    Nekljudova, V.
    Lin, Y.
    Wolmark, N.
    Geyer, C.
    ANNALS OF ONCOLOGY, 2020, 31 : S339 - S339
12345